ASCIA treatment guideline for chronic spontaneous urticaria (Australia)

Whilst the pathway shaded in green is approved by TGA/PBS, ASCIA recommends that some patients may benefit from omalizumab who have a lower UAS, as supported by clinical trial data.

* Note: H2 antagonists are now difficult to source and the evidence base for efficacy in chronic spontaneous urticaria is weak, so ASCIA recommends a treatment trial of high dose antihistamines in combination with montelukast, before applying for omalizumab.

© ASCIA 2020
ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand